Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles V Pollack

Showing results (1-10 of 232) with videos related to

Pageof 24
Sort By:
Circulation|March 31, 2016
Cardiology Patient Pages: Antidotes for Bleeding Caused by Novel Oral AnticoagulantsCharles V Pollack
The Journal of Emergency Medicine|January 30, 2003
Utility of platelet adp receptor antagonism in the emergency department: a reviewCharles V Pollack
The American Journal of Cardiology|March 12, 2021
ISSUE INTRODUCTION: The Diminishing Role of Aspirin in Cardiovascular Medicine: A Special Supplement to The American Journal of CardiologyCharles V Pollack
Emergency Medicine Journal : EMJ|May 20, 2015
Coagulation assessment with the new generation of oral anticoagulantsCharles V Pollack
The Journal of Emergency Medicine|June 22, 2013
Managing bleeding in anticoagulated patients in the emergency care settingCharles V Pollack
The American Journal of Emergency Medicine|October 5, 2016
Evidence supporting idarucizumab for the reversal of dabigatranCharles V Pollack
The American Journal of Emergency Medicine|October 5, 2016
Introduction to direct oral anticoagulants and rationale for specific reversal agentsCharles V Pollack
The American Journal of Medicine|August 14, 2016
Introduction to Direct Oral Anticoagulants and Rationale for Specific Reversal AgentsCharles V Pollack
The American Journal of Emergency Medicine|July 2, 2013
Upstream antiactivation antiplatelet therapy: first, do no harm. Then consider doing some goodCharles V Pollack
The American Journal of Medicine|August 29, 2016
Evidence Supporting Idarucizumab for the Reversal of DabigatranCharles V Pollack
Pageof 24

Showing results (1-10 of 232) with videos related to

Sort By:
Pageof 24
Circulation|March 31, 2016
Cardiology Patient Pages: Antidotes for Bleeding Caused by Novel Oral AnticoagulantsCharles V Pollack
The Journal of Emergency Medicine|January 30, 2003
Utility of platelet adp receptor antagonism in the emergency department: a reviewCharles V Pollack
The American Journal of Cardiology|March 12, 2021
ISSUE INTRODUCTION: The Diminishing Role of Aspirin in Cardiovascular Medicine: A Special Supplement to The American Journal of CardiologyCharles V Pollack
Emergency Medicine Journal : EMJ|May 20, 2015
Coagulation assessment with the new generation of oral anticoagulantsCharles V Pollack
The Journal of Emergency Medicine|June 22, 2013
Managing bleeding in anticoagulated patients in the emergency care settingCharles V Pollack
The American Journal of Emergency Medicine|October 5, 2016
Evidence supporting idarucizumab for the reversal of dabigatranCharles V Pollack
The American Journal of Emergency Medicine|October 5, 2016
Introduction to direct oral anticoagulants and rationale for specific reversal agentsCharles V Pollack
The American Journal of Medicine|August 14, 2016
Introduction to Direct Oral Anticoagulants and Rationale for Specific Reversal AgentsCharles V Pollack
The American Journal of Emergency Medicine|July 2, 2013
Upstream antiactivation antiplatelet therapy: first, do no harm. Then consider doing some goodCharles V Pollack
The American Journal of Medicine|August 29, 2016
Evidence Supporting Idarucizumab for the Reversal of DabigatranCharles V Pollack
Pageof 24